Johnson & Johnson (JNJ)

$232.16 -0.61 (-0.26%)
Market Cap 560.33B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.26
Forward PE 19.72
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 7,559,700
Avg Vol 7,601,534
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 79%
Beta 0.26
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
ewforecast
ewforecast Jun. 9 at 7:48 AM
$JNJ Johnson & Johnson Update: Wave 4 Correction May Be Nearing Completion After Wave 3 Extension #JohnsonNJohnson #elliottwave Check it below https://wavetraders.com/free-charts/johnson-johnson-update-wave-4-correction-may-be-nearing-completion-jun-09-2026/
0 · Reply
freedomtrader6
freedomtrader6 Jun. 8 at 9:16 PM
$NOW Okay, hear me out… AI stocks are getting nuts, and maybe it’s time to park some cash in something that actually works. These four healthcare giants are my go-to: $LLY – Crushing it in obesity & diabetes $MRK – Cash-printing pharma machine $UNH – Insurance kingpin $JNJ – Diversified healthcare beast They’re not flashy, but that’s the point steady, reliable, and they make money while everyone else panics. Honestly, sometimes boring wins.
0 · Reply
notreload_ai
notreload_ai Jun. 8 at 3:15 PM
$JNJ is acquiring Firefly Bio for $1 billion to expand its cancer pipeline. The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue. https://notreload.xyz/xy/jnj-buys-firefly-bio-for-1b-to-fight-kras-cancer/
0 · Reply
BetaLaboratory
BetaLaboratory Jun. 8 at 2:08 PM
$JNJ's $1B move on Firefly Bio shows it's still willing to bet aggressively on innovation. Large pharma needs new growth engines, and biotech acquisitions remain one of the fastest ways to strengthen the pipeline and access next-generation therapies.
0 · Reply
TrendOriented
TrendOriented Jun. 8 at 1:55 PM
$OKLO Oklo just announced it is acquiring ARMEC, a precision manufacturing and engineering firm. Another step toward vertical integration in advanced nuclear and clean energy infrastructure. $JNJ Johnson & Johnson also moving, agreeing to acquire Firefly Bio for $1B, continuing its push into next-gen biotech innovation. M&A is clearly picking up again. When big players start consolidating tech and bio assets, it usually signals where the next cycle of growth is being built.
0 · Reply
focafoca99
focafoca99 Jun. 8 at 12:58 PM
$JNJ commits to acquire Firefly Bio for $1 billion, expanding its oncology pipeline with a novel degrader antibody platform. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-acquire-a0104a
0 · Reply
HydrogenH2
HydrogenH2 Jun. 8 at 10:26 AM
$JNJ When Cramer "Pumping" this... ???
0 · Reply
TheStockTraderHub
TheStockTraderHub Jun. 8 at 5:12 AM
$JNJ forming a sweet reversal on daily, managed to close above it's .786 fib level on friday. $234 break & close on watch for a bigger move towards $240/$245+ in coming days. Support: $228
0 · Reply
TheStockTraderHub
TheStockTraderHub Jun. 8 at 5:06 AM
$JNJ forming a sweet reversal on daily, managed to close above it's .786 fib level on friday. $234 break & close on watch for a bigger move towards $240/$245+ in coming days. Support: $228
0 · Reply
Ron_Burn
Ron_Burn Jun. 7 at 1:19 PM
$JNJ
0 · Reply
Latest News on JNJ
M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

2026-06-08T13:00:56.000Z - 19 hours ago

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

Johnson & Johnson to acquire Firefly Bio for $1B in cash

2026-06-08T12:14:56.000Z - 20 hours ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 20 hours ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 8, 2026, 8:00 AM EDT - 20 hours ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 5, 2026, 6:24 PM EDT - 3 days ago

J&J beats lawsuit alleging that talc caused three women's cancer

Johnson & Johnson presents exploratory analyses from DAHLIAS study

2026-06-03T09:38:11.000Z - 5 days ago

Johnson & Johnson presents exploratory analyses from DAHLIAS study

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

2026-06-03T09:31:04.000Z - 5 days ago

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Jun 3, 2026, 12:04 AM EDT - 6 days ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 3, 2026, 12:03 AM EDT - 6 days ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

Jun 2, 2026, 6:24 PM EDT - 6 days ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

2026-05-31T21:41:49.000Z - 8 days ago

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

2026-05-31T21:40:07.000Z - 8 days ago

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:39 AM EDT - 8 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:29 AM EDT - 8 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:27 AM EDT - 8 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 31, 2026, 8:01 AM EDT - 8 days ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 2:00 PM EDT - 10 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

2026-05-29T12:49:22.000Z - 10 days ago

Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 29, 2026, 8:18 AM EDT - 10 days ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 7:10 PM EDT - 11 days ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 28, 2026, 5:30 AM EDT - 11 days ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 4:22 PM EDT - 12 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 27, 2026, 11:00 AM EDT - 12 days ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 7:00 AM EDT - 18 days ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 18 days ago

Johnson & Johnson says nipocalimab approved in China

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:30 AM EDT - 20 days ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 19, 2026, 9:00 AM EDT - 20 days ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14, 2026, 4:01 PM EDT - 25 days ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:20 PM EDT - 27 days ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 12, 2026, 7:45 AM EDT - 27 days ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 4:34 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 11, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 11:34 AM EDT - 4 weeks ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

MO

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 7, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 4 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

May 5, 2026, 8:05 AM EDT - 4 weeks ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 8:05 AM EDT - 4 weeks ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 5, 2026, 7:00 AM EDT - 4 weeks ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 4, 2026, 8:00 AM EDT - 5 weeks ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 5 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 30, 2026, 8:02 AM EDT - 5 weeks ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 5 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 4:33 PM EDT - 6 weeks ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 6 weeks ago

J&J sees AI halving the time to generate drug development leads

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 27, 2026, 8:03 AM EDT - 6 weeks ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 24, 2026, 4:30 PM EDT - 6 weeks ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Cramer says look to these 4 stocks to go with your high-flying tech names

Apr 23, 2026, 6:44 PM EDT - 6 weeks ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: AGM 2026

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 8:05 AM EDT - 6 weeks ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 22, 2026, 4:00 AM EDT - 6 weeks ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 4:22 PM EDT - 6 weeks ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 21, 2026, 7:45 AM EDT - 6 weeks ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 10:36 PM EDT - 7 weeks ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 7 weeks ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 15, 2026, 4:11 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 7 weeks ago

Johnson & Johnson CFO on the company's robotic surgical system

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

Apr 14, 2026, 10:30 AM EDT - 7 weeks ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Johnson & Johnson Earnings Call Transcript: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings Call Transcript: Q1 2026

Johnson & Johnson Earnings release: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings release: Q1 2026

Johnson & Johnson Slides: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Slides: Q1 2026

Johnson & Johnson Quarterly report: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Quarterly report: Q1 2026

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 7 weeks ago

J&J raises guidance for 2026 on strong start to the year

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:25 AM EDT - 7 weeks ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:21 AM EDT - 7 weeks ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 7 weeks ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

ewforecast
ewforecast Jun. 9 at 7:48 AM
$JNJ Johnson & Johnson Update: Wave 4 Correction May Be Nearing Completion After Wave 3 Extension #JohnsonNJohnson #elliottwave Check it below https://wavetraders.com/free-charts/johnson-johnson-update-wave-4-correction-may-be-nearing-completion-jun-09-2026/
0 · Reply
freedomtrader6
freedomtrader6 Jun. 8 at 9:16 PM
$NOW Okay, hear me out… AI stocks are getting nuts, and maybe it’s time to park some cash in something that actually works. These four healthcare giants are my go-to: $LLY – Crushing it in obesity & diabetes $MRK – Cash-printing pharma machine $UNH – Insurance kingpin $JNJ – Diversified healthcare beast They’re not flashy, but that’s the point steady, reliable, and they make money while everyone else panics. Honestly, sometimes boring wins.
0 · Reply
notreload_ai
notreload_ai Jun. 8 at 3:15 PM
$JNJ is acquiring Firefly Bio for $1 billion to expand its cancer pipeline. The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue. https://notreload.xyz/xy/jnj-buys-firefly-bio-for-1b-to-fight-kras-cancer/
0 · Reply
BetaLaboratory
BetaLaboratory Jun. 8 at 2:08 PM
$JNJ's $1B move on Firefly Bio shows it's still willing to bet aggressively on innovation. Large pharma needs new growth engines, and biotech acquisitions remain one of the fastest ways to strengthen the pipeline and access next-generation therapies.
0 · Reply
TrendOriented
TrendOriented Jun. 8 at 1:55 PM
$OKLO Oklo just announced it is acquiring ARMEC, a precision manufacturing and engineering firm. Another step toward vertical integration in advanced nuclear and clean energy infrastructure. $JNJ Johnson & Johnson also moving, agreeing to acquire Firefly Bio for $1B, continuing its push into next-gen biotech innovation. M&A is clearly picking up again. When big players start consolidating tech and bio assets, it usually signals where the next cycle of growth is being built.
0 · Reply
focafoca99
focafoca99 Jun. 8 at 12:58 PM
$JNJ commits to acquire Firefly Bio for $1 billion, expanding its oncology pipeline with a novel degrader antibody platform. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-acquire-a0104a
0 · Reply
HydrogenH2
HydrogenH2 Jun. 8 at 10:26 AM
$JNJ When Cramer "Pumping" this... ???
0 · Reply
TheStockTraderHub
TheStockTraderHub Jun. 8 at 5:12 AM
$JNJ forming a sweet reversal on daily, managed to close above it's .786 fib level on friday. $234 break & close on watch for a bigger move towards $240/$245+ in coming days. Support: $228
0 · Reply
TheStockTraderHub
TheStockTraderHub Jun. 8 at 5:06 AM
$JNJ forming a sweet reversal on daily, managed to close above it's .786 fib level on friday. $234 break & close on watch for a bigger move towards $240/$245+ in coming days. Support: $228
0 · Reply
Ron_Burn
Ron_Burn Jun. 7 at 1:19 PM
$JNJ
0 · Reply
Randomizer123
Randomizer123 Jun. 6 at 3:31 PM
$LEGN Merck will be losing exclusivity soon (2028) on cancer drug Keytruda which brings $32B revenue annually. They are in the $LEGN’s backyard (Philadelphia) similar to $JNJ
0 · Reply
LewisDaKat
LewisDaKat Jun. 6 at 3:00 PM
$JNJ Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock https://marketwirenews.com/stock/jnj/news/why-johnson-johnson-may-be-the-closest-thing-investo-8693708258825211.html?utm_source=stocktwits
0 · Reply
Randomizer123
Randomizer123 Jun. 6 at 2:02 PM
$LEGN Legend Biotech’s CEO is effectively giving an ultimatum to $JNJ. By saying in the WSJ that he’s open to a limited partnership on in vivo CAR-T for lymphoma, he’s courting bidders. Once negotiations on the in vivo CAR-T deal reach an advanced stage, he’ll tack on the remaining 50% of the Carvykti franchise as part of the deal and sell the company. Watch out for reactions to the June 14 oral presentation. Would be surprised if a buyout didn’t happen by EOY, may be by fall 2026.
2 · Reply
clan
clan Jun. 6 at 10:41 AM
$MNKD 🚨 FDA Approved 🚨 Signs of Afrezza adoption will be forthcoming. Helping little kiddos with a life-altering medical affliction. Stay tuned. #approved #trolltrigger $SPY $JNJ $UNH
0 · Reply
ADelightfulman
ADelightfulman Jun. 6 at 6:47 AM
$KGC technical buy zone! $DRAM $SPMO $SCHD Added today. $JNJ on 🔥! Make sure you’re not Q’d up!
0 · Reply
MarketMaestro1
MarketMaestro1 Jun. 5 at 9:04 PM
While tech was selling off aggressively… defensive names quietly outperformed: $CL +4% $KO +3% $JNJ +2% This is classic risk rotation. Capital is not leaving the market. It’s rotating. The key signal is not panic—it’s positioning.
2 · Reply
OptionRunners
OptionRunners Jun. 5 at 6:57 PM
$JNJ calls are almost $6 now
0 · Reply
WunDumFuc
WunDumFuc Jun. 5 at 6:14 PM
$SPY $CAG $WMT $JNJ $PFE STAPLES are NO safety in this market: Increased production costs due to inflation as result of oil being higher and commodities higher. Staple companies have ZERO pricing power in this market with broken consumer. HE can fix 70% of issues over weekend by UNBLOCKING STRAIGHT…he is keeping it closed
0 · Reply
imjustjimmymoore
imjustjimmymoore Jun. 5 at 4:09 PM
$BTC.X $XRP.X $MRNA $JNJ Cancer Fight 101 https://www.tiktok.com/t/ZP8s6gM1f/
0 · Reply
BreakoutsHappen
BreakoutsHappen Jun. 5 at 3:37 PM
Healthcare works well $LLY $UNH $JNJ $MRK
0 · Reply
JRIGWM
JRIGWM Jun. 5 at 3:31 PM
95.51% as of 6/5/2026 Rebalancing today. Keep an eye on your HYSA interest rates. Many have gone down the past few months. However, there are some bonus deals out there exceeding national averages. Added to $SCHD and $PFFA. Next dividend $JNJ 6/10, $MSFT 6/12.
0 · Reply
JRIGWM
JRIGWM Jun. 5 at 3:30 PM
95.51% as of 6/5/2026 Rebalancing today. Keep an eye on your HYSA interest rates. Many have gone down the past few months. However, there are some bonus deals out there exceeding national averages. Added to $SCHD and $PFFA. Next dividend $JNJ 6/10, $MSFT 6/12.
0 · Reply